Literature DB >> 26492874

Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis.

P Vidya, L Smith, T Beaudoin, Y C Yau, S Clark, B Coburn, D S Guttman, D M Hwang, V Waters.   

Abstract

Early eradication treatment with inhaled tobramycin is successful in the majority of children with cystic fibrosis (CF) with incident Pseudomonas aeruginosa infection. However, in 10-40 % of cases, eradication fails and the reasons for this are poorly understood. The purpose of this study was to determine whether specific microbial characteristics could explain eradication treatment failure. This was a cross-sectional study of CF patients (aged 0-18 years) with incident P. aeruginosa infection from 2011 to 2014 at the Hospital for Sick Children, Toronto, Canada. Phenotypic assays were done on all incident P. aeruginosa isolates, and eradicated and persistent isolates were compared using the Mann-Whitney test or the two-sided Chi-square test. A total of 46 children with CF had 51 incident P. aeruginosa infections. In 72 % (33/46) of the patients, eradication treatment was successful, while 28 % failed eradication therapy. Persistent isolates were less likely to be motile, with significantly less twitch motility (p=0.001), were more likely to be mucoid (p=0.002), and more likely to have a tobramycin minimum inhibitory concentration (MIC) ≥ 128 μg/mL (p=0.02) compared to eradicated isolates. Although biofilm production was similar, there was a trend towards more persistent isolates with deletions in quorum-sensing genes compared with eradicated isolates (p=0.06). Initial acquisition of P. aeruginosa with characteristics of chronic infection is associated with failure of eradication treatment.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26492874     DOI: 10.1007/s10096-015-2509-4

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  33 in total

1.  Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.

Authors:  Nicole Mayer-Hamblett; Richard A Kronmal; Ronald L Gibson; Margaret Rosenfeld; George Retsch-Bogart; Miriam M Treggiari; Jane L Burns; Umer Khan; Bonnie W Ramsey
Journal:  Pediatr Pulmonol       Date:  2011-08-09

2.  Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis.

Authors:  R L Henry; C M Mellis; L Petrovic
Journal:  Pediatr Pulmonol       Date:  1992-03

3.  Differential mucoid exopolysaccharide production by members of the Burkholderia cepacia complex.

Authors:  James E A Zlosnik; Trevor J Hird; Monica C Fraenkel; Leonilde M Moreira; Deborah A Henry; David P Speert
Journal:  J Clin Microbiol       Date:  2008-02-06       Impact factor: 5.948

4.  Impact of Sustained Eradication of New Pseudomonas aeruginosa Infection on Long-term Outcomes in Cystic Fibrosis.

Authors:  Nicole Mayer-Hamblett; Margaret Kloster; Margaret Rosenfeld; Ronald L Gibson; George Z Retsch-Bogart; Julia Emerson; Valeria Thompson; Bonnie W Ramsey
Journal:  Clin Infect Dis       Date:  2015-05-13       Impact factor: 9.079

5.  Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis.

Authors:  Zhanhai Li; Michael R Kosorok; Philip M Farrell; Anita Laxova; Susan E H West; Christopher G Green; Jannette Collins; Michael J Rock; Mark L Splaingard
Journal:  JAMA       Date:  2005-02-02       Impact factor: 56.272

Review 6.  Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung.

Authors:  Michael Hogardt; Jürgen Heesemann
Journal:  Int J Med Microbiol       Date:  2010-10-12       Impact factor: 3.473

7.  Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis.

Authors:  Miriam M Treggiari; George Retsch-Bogart; Nicole Mayer-Hamblett; Umer Khan; Michal Kulich; Richard Kronmal; Judy Williams; Peter Hiatt; Ronald L Gibson; Terry Spencer; David Orenstein; Barbara A Chatfield; Deborah K Froh; Jane L Burns; Margaret Rosenfeld; Bonnie W Ramsey
Journal:  Arch Pediatr Adolesc Med       Date:  2011-09

8.  Effectiveness of inhaled tobramycin in eradicating Pseudomonas aeruginosa in children with cystic fibrosis.

Authors:  Sanja Stanojevic; Valerie Waters; Joseph L Mathew; Louise Taylor; Felix Ratjen
Journal:  J Cyst Fibros       Date:  2013-10-03       Impact factor: 5.482

9.  Geographical differences in first acquisition of Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Sarath C Ranganathan; Billy Skoric; Kay A Ramsay; Rosemary Carzino; Anne-Marie Gibson; Emily Hart; Jo Harrison; Scott C Bell; Timothy J Kidd
Journal:  Ann Am Thorac Soc       Date:  2013-04

10.  Predictors of mucoid Pseudomonas colonization in cystic fibrosis patients.

Authors:  Hara Levy; Leslie A Kalish; Carolyn L Cannon; K Christopher García; Craig Gerard; Don Goldmann; Gerald B Pier; Scott T Weiss; A A Colin
Journal:  Pediatr Pulmonol       Date:  2008-05
View more
  12 in total

1.  Determinants for persistence of Pseudomonas aeruginosa in hospitals: interplay between resistance, virulence and biofilm formation.

Authors:  S J Kaiser; N T Mutters; A DeRosa; C Ewers; U Frank; F Günther
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-10-12       Impact factor: 3.267

2.  Visualizing the Effects of Sputum on Biofilm Development Using a Chambered Coverglass Model.

Authors:  Trevor Beaudoin; Sarah Kennedy; Yvonne Yau; Valerie Waters
Journal:  J Vis Exp       Date:  2016-12-14       Impact factor: 1.355

3.  Engineered cationic antimicrobial peptide (eCAP) prevents Pseudomonas aeruginosa biofilm growth on airway epithelial cells.

Authors:  Lauren P Lashua; Jeffrey A Melvin; Berthony Deslouches; Joseph M Pilewski; Ronald C Montelaro; Jennifer M Bomberger
Journal:  J Antimicrob Chemother       Date:  2016-05-26       Impact factor: 5.790

4.  Filamentous bacteriophages are associated with chronic Pseudomonas lung infections and antibiotic resistance in cystic fibrosis.

Authors:  Elizabeth B Burgener; Johanna M Sweere; Michelle S Bach; Patrick R Secor; Naomi Haddock; Laura K Jennings; Rasmus L Marvig; Helle Krogh Johansen; Elio Rossi; Xiou Cao; Lu Tian; Laurence Nedelec; Søren Molin; Paul L Bollyky; Carlos E Milla
Journal:  Sci Transl Med       Date:  2019-04-17       Impact factor: 17.956

5.  Pseudomonas aeruginosa Type III Secretion System Virulotypes and Their Association with Clinical Features of Cystic Fibrosis Patients.

Authors:  Edilene do Socorro Nascimento Falcão Sarges; Yan Corrêa Rodrigues; Ismari Perini Furlaneto; Marcos Vinicios Hino de Melo; Giulia Leão da Cunha Brabo; Kátia Cilene Machado Lopes; Ana Judith Pires Garcia Quaresma; Luana Nepomuceno Godim Costa Lima; Karla Valéria Batista Lima
Journal:  Infect Drug Resist       Date:  2020-10-22       Impact factor: 4.003

6.  Longitudinal development of initial, chronic and mucoid Pseudomonas aeruginosa infection in young children with cystic fibrosis.

Authors:  S L Heltshe; U Khan; V Beckett; A Baines; J Emerson; D B Sanders; R L Gibson; W Morgan; M Rosenfeld
Journal:  J Cyst Fibros       Date:  2017-10-28       Impact factor: 5.482

7.  Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance.

Authors:  T Beaudoin; Y C W Yau; P J Stapleton; Y Gong; P W Wang; D S Guttman; V Waters
Journal:  NPJ Biofilms Microbiomes       Date:  2017-10-19       Impact factor: 7.290

8.  "Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Authors:  Peter H Gilligan; Damian G Downey; J Stuart Elborn; Patrick A Flume; Sebastian Funk; Deirdre Gilpin; Timothy J Kidd; John McCaughan; B Cherie Millar; Philip G Murphy; Jacqueline C Rendall; Michael M Tunney; John E Moore
Journal:  J Clin Microbiol       Date:  2018-08-27       Impact factor: 5.948

9.  Aerosolized Bovine Lactoferrin Counteracts Infection, Inflammation and Iron Dysbalance in A Cystic Fibrosis Mouse Model of Pseudomonas aeruginosa Chronic Lung Infection.

Authors:  Antimo Cutone; Maria Stefania Lepanto; Luigi Rosa; Mellani Jinnett Scotti; Alice Rossi; Serena Ranucci; Ida De Fino; Alessandra Bragonzi; Piera Valenti; Giovanni Musci; Francesca Berlutti
Journal:  Int J Mol Sci       Date:  2019-04-30       Impact factor: 5.923

Review 10.  Microbiology of Cystic Fibrosis Airway Disease.

Authors:  Ana C Blanchard; Valerie J Waters
Journal:  Semin Respir Crit Care Med       Date:  2019-12-30       Impact factor: 3.119

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.